|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MELTF |
Gene summary for MELTF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MELTF | Gene ID | 4241 |
| Gene name | melanotransferrin | |
| Gene Alias | CD228 | |
| Cytomap | 3q29 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P08582 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4241 | MELTF | PTC05 | Human | Thyroid | PTC | 3.09e-10 | 4.78e-01 | 0.2065 |
| 4241 | MELTF | PTC06 | Human | Thyroid | PTC | 1.27e-10 | 3.48e-01 | 0.2057 |
| 4241 | MELTF | PTC07 | Human | Thyroid | PTC | 7.95e-06 | 2.11e-01 | 0.2044 |
| 4241 | MELTF | ATC09 | Human | Thyroid | ATC | 1.86e-08 | 4.31e-01 | 0.2871 |
| 4241 | MELTF | ATC11 | Human | Thyroid | ATC | 2.13e-10 | 7.93e-01 | 0.3386 |
| 4241 | MELTF | ATC12 | Human | Thyroid | ATC | 2.71e-07 | 2.06e-01 | 0.34 |
| 4241 | MELTF | ATC13 | Human | Thyroid | ATC | 1.29e-04 | 1.14e-01 | 0.34 |
| 4241 | MELTF | ATC1 | Human | Thyroid | ATC | 1.42e-10 | 5.22e-01 | 0.2878 |
| 4241 | MELTF | ATC2 | Human | Thyroid | ATC | 1.03e-16 | 1.32e+00 | 0.34 |
| 4241 | MELTF | ATC3 | Human | Thyroid | ATC | 2.25e-14 | 8.00e-01 | 0.338 |
| 4241 | MELTF | ATC4 | Human | Thyroid | ATC | 3.30e-10 | 2.60e-01 | 0.34 |
| 4241 | MELTF | ATC5 | Human | Thyroid | ATC | 1.70e-05 | 1.33e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022411113 | Thyroid | PTC | cellular component disassembly | 232/5968 | 443/18723 | 1.36e-19 | 1.75e-17 | 232 |
| GO:0045862113 | Thyroid | PTC | positive regulation of proteolysis | 198/5968 | 372/18723 | 6.68e-18 | 6.91e-16 | 198 |
| GO:0022604112 | Thyroid | PTC | regulation of cell morphogenesis | 165/5968 | 309/18723 | 2.60e-15 | 1.82e-13 | 165 |
| GO:0010810112 | Thyroid | PTC | regulation of cell-substrate adhesion | 113/5968 | 221/18723 | 1.87e-09 | 5.28e-08 | 113 |
| GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
| GO:0010769111 | Thyroid | PTC | regulation of cell morphogenesis involved in differentiation | 57/5968 | 96/18723 | 2.50e-08 | 5.62e-07 | 57 |
| GO:005160420 | Thyroid | PTC | protein maturation | 132/5968 | 294/18723 | 1.71e-06 | 2.39e-05 | 132 |
| GO:0034446111 | Thyroid | PTC | substrate adhesion-dependent cell spreading | 58/5968 | 108/18723 | 2.07e-06 | 2.82e-05 | 58 |
| GO:1900024111 | Thyroid | PTC | regulation of substrate adhesion-dependent cell spreading | 35/5968 | 57/18723 | 4.20e-06 | 5.20e-05 | 35 |
| GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
| GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
| GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
| GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
| GO:0055076110 | Thyroid | PTC | transition metal ion homeostasis | 62/5968 | 138/18723 | 8.66e-04 | 5.30e-03 | 62 |
| GO:19030554 | Thyroid | PTC | positive regulation of extracellular matrix organization | 16/5968 | 25/18723 | 9.53e-04 | 5.72e-03 | 16 |
| GO:19030533 | Thyroid | PTC | regulation of extracellular matrix organization | 26/5968 | 48/18723 | 1.13e-03 | 6.59e-03 | 26 |
| GO:005507210 | Thyroid | PTC | iron ion homeostasis | 39/5968 | 85/18723 | 4.71e-03 | 2.21e-02 | 39 |
| GO:00107554 | Thyroid | PTC | regulation of plasminogen activation | 9/5968 | 13/18723 | 6.33e-03 | 2.79e-02 | 9 |
| GO:000716219 | Thyroid | PTC | negative regulation of cell adhesion | 117/5968 | 303/18723 | 7.28e-03 | 3.12e-02 | 117 |
| GO:002241124 | Thyroid | ATC | cellular component disassembly | 248/6293 | 443/18723 | 1.34e-22 | 3.69e-20 | 248 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MELTF | SNV | Missense_Mutation | rs778156728 | c.850N>T | p.Arg284Trp | p.R284W | P08582 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
| MELTF | SNV | Missense_Mutation | c.1472N>A | p.Gly491Asp | p.G491D | P08582 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MELTF | SNV | Missense_Mutation | rs745564030 | c.799N>A | p.Glu267Lys | p.E267K | P08582 | protein_coding | tolerated(0.08) | benign(0.352) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
| MELTF | SNV | Missense_Mutation | rs202082579 | c.454C>T | p.Arg152Cys | p.R152C | P08582 | protein_coding | tolerated(0.15) | possibly_damaging(0.809) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| MELTF | SNV | Missense_Mutation | rs767709260 | c.1402N>T | p.Asp468Tyr | p.D468Y | P08582 | protein_coding | deleterious(0.01) | possibly_damaging(0.721) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| MELTF | SNV | Missense_Mutation | c.496N>C | p.Asp166His | p.D166H | P08582 | protein_coding | deleterious(0.04) | benign(0.111) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| MELTF | SNV | Missense_Mutation | c.178N>C | p.Ala60Pro | p.A60P | P08582 | protein_coding | tolerated(0.2) | benign(0.042) | TCGA-D8-A27T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| MELTF | SNV | Missense_Mutation | novel | c.1423T>C | p.Ser475Pro | p.S475P | P08582 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A158-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | arimidex | SD |
| MELTF | SNV | Missense_Mutation | novel | c.2117C>T | p.Ser706Phe | p.S706F | P08582 | protein_coding | deleterious(0.04) | possibly_damaging(0.694) | TCGA-LL-A50Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
| MELTF | SNV | Missense_Mutation | novel | c.1939N>T | p.Asp647Tyr | p.D647Y | P08582 | protein_coding | deleterious(0.02) | possibly_damaging(0.879) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |